Browse News
Filter News
Found 685,398 articles
-
A day after the FDA authorized a COVID-19 booster dose of the Pfizer-BioNTech vaccine, a U.S. Centers for Disease Control and Prevention advisory committee voted in support.
-
Aside from the fraud trial of Theranos founder Elizabeth Holmes, other court-related cases are taking place, including between Takeda and AbbVie over cancer drug, Lupron.
-
Esker Therapeutics tapped Martin Babler to helm the company after founding CEO June Lee has stepped away to pursue other opportunities.
-
Study: Adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TILs) is more effective in patients who have not been treated with checkpoint inhibitors than in those who have undergone one or more therapies.
-
The National Kidney Foundation and the American Society of Nephrology recommend removing race from the equation in the assessment of kidney disease.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Researchers from the Max Planck Institute for Heart and Lung Research reportedly achieved positive results after returning adult cardiomyocytes to their fetal-like state in mouse models.
-
CPhI Report predicts record EBITDAs for CDMOs in 2022
9/24/2021
Part one of the 2021 CPhI Annual Report predicts an increasingly bullish outlook for CDMOs in the next 2-3 years, with macro factors significantly driving up demand and prices for mergers and acquisitions.
-
Kizoo Portfolio Company Underdog Closes $10M Financing Round
9/24/2021
Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
-
Scipher Medicine Welcomes Sam Davis as General Counsel
9/24/2021
Scipher Medicine today announced the appointment of Sam A. Davis, JD, as General Counsel.
-
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
9/24/2021
Research aims to confirm evidence of the expression of human endogenous retrovirus W envelope protein (HERV-W ENV or W-ENV) in long-haul COVID patients, and identify affected patients who may benefit from a treatment with GeNeuro’s temelimab.
-
Instadose Pharma Corp Merger
9/24/2021
Instadose Pharma Corp. today announced that it has entered into a plan of arrangement to acquire all the issued and outstanding shares of Instadose Pharma Corp., a corporation organized under the laws of Canada.
-
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
9/24/2021
Onconova Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $4.20 per share.
-
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market
9/24/2021
Kintara Therapeutics, Inc. today announced that it has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise approximately $15 million in gross proceeds
-
Ventus Therapeutics to Present Data for Novel Peripherally Restricted and Brain-Penetrant NLRP3 Small Molecule Inhibitors for the Treatment of Inflammatory and Neurological Diseases
9/24/2021
Ventus Therapeutics, Inc. presented data for its NLRP3 inhibitor program at today’s 2021 EMBO Inflammasome Workshop.
-
SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19
9/24/2021
SAB Biotherapeutics announced that an independent Data Safety Monitoring Board has completed its prespecified interim analysis data review of the safety and efficacy of SAB-185 in the Phase 2 portion of the ACTIV-2 trial and has recommended advancement to Phase 3.
-
Covalon Announces Retirement of Board Member
9/24/2021
Covalon Technologies Ltd. today announces that Dr. Myrna Francis is retiring as a member of the Board of Directors of the Company, effective September 24th , 2021
-
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
9/24/2021
A group of long-time stockholders today announced its comprehensive strategic plan to obtain cancer therapy approval for Leronlimab.